We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is the Options Market Predicting a Spike in Idera Pharmaceuticals (IDRA) Stock?
Read MoreHide Full Article
Investors in shares of Idera Pharmaceuticals, Inc. need to pay close attention to the stock based on moves in the options market lately. That is because the Put which expires on Dec 17, 2016 for the $3.00 strike price had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility could mean that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that could cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Idera Pharmaceuticals shares, but what is the fundamental picture for the company? Currently, Idera Pharmaceuticals is a Zacks Rank #2 (Buy) in the Medical - Biomedical and Genetics industry that ranks in the top 24% of our Zacks Industry Rank. Over the last 60 days, three analysts have increased their earnings estimates for the current quarter, while none have dropped the estimate. The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of 11 cents per share to a loss of 8 cents per share in that period.
Given the way analysts feel about Idera Pharmaceuticals right now, this huge implied volatility could mean there’s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Looking to Trade Options?
Each week, our very own Dave Bartosiak gives his top options trades. Check out his recent live analysis and options trade for the LULU earnings report completely free. See it here: Bartosiak: Trading Lululemon (LULU) Earnings with Options or check out the embed video below for more details:
Image: Bigstock
Is the Options Market Predicting a Spike in Idera Pharmaceuticals (IDRA) Stock?
Investors in shares of Idera Pharmaceuticals, Inc. need to pay close attention to the stock based on moves in the options market lately. That is because the Put which expires on Dec 17, 2016 for the $3.00 strike price had some of the highest implied volatility of all equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility could mean that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that could cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Idera Pharmaceuticals shares, but what is the fundamental picture for the company? Currently, Idera Pharmaceuticals is a Zacks Rank #2 (Buy) in the Medical - Biomedical and Genetics industry that ranks in the top 24% of our Zacks Industry Rank. Over the last 60 days, three analysts have increased their earnings estimates for the current quarter, while none have dropped the estimate. The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of 11 cents per share to a loss of 8 cents per share in that period.
Given the way analysts feel about Idera Pharmaceuticals right now, this huge implied volatility could mean there’s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Looking to Trade Options?
Each week, our very own Dave Bartosiak gives his top options trades. Check out his recent live analysis and options trade for the LULU earnings report completely free. See it here: Bartosiak: Trading Lululemon (LULU) Earnings with Options or check out the embed video below for more details: